OraSure Technologies, Inc. headquartered in Bethlem, Pennsylvania, announced that its OMNIgene·ORAL collection device was included in the U.S.FDA Emergency Use Authorization granted to 3B BlackBio Biotech, one of the leading suppliers and developers for RT-PCR diagnostic assays in India.
This enable qualitative detection of nucleic acid from SARS-CoV-2 in saliva specimens that are collected with the assistance of a healthcare provider using the OMNIgene·ORAL saliva collection device. A product of OraSure’s DNA Genotek subsidiary, the saliva collection devices are intended for use by individuals to collect and immediately stabilize saliva specimens suspected of containing SARS-CoV-2 RNA at ambient temperature for transport.
“3B BlackBio Biotech aims at fulfilling the current demand of higher testing and has stepped up its production capacity for RT-PCR kit for SARS-CoV-2 detection. Our kit coupled with the Saliva Specimen Collection Device of OraSure’s DNA Genotek (based in Ottawa, Canada) will make the sampling easier for the healthcare service provider and will also reduce the patient’s discomfort,” said Dhirendra Dubey, Managing Director, 3B BlackBio Biotech India Limited, located in Bhopal, India
